Clinical Trial

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

Spryte Medical's new trial is testing a device that gives surgeons a real-time, microscopic view inside brain arteries for the first time.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.